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Objectives: To investigate the natural history of men with low levels of baseline prostate-
speciﬁc antigen in terms of risk of increased prostate-speciﬁc antigen, developing prostate
cancer and also the likelihood of detecting clinically insigniﬁcant cancer in population-based
screening.
Methods: A total of 10 653 men aged between 55 and 68 years with baseline prostate-
speciﬁc antigen levels of 2.0 ng/mL or lower screened annually were enrolled. The cumulative
risks of increased prostate-speciﬁc antigen and developing cancer were investigated. The
relationships of baseline prostate-speciﬁc antigen with clinicopathological features of
screening-detected cancer were also investigated.
Results: A total of 1405 men (13.2%) showed serum prostate-speciﬁc antigen above
2.0 ng/mL and 68 (0.6%) were diagnosed with prostate cancer during the observation period.
Cumulative probabilities of increased prostate-speciﬁc antigen above 2.0 ng/mL over 10
years were 7.7%, 18.3%, 57.3%, and 88.7% inmenwith baseline prostate-speciﬁc antigen levels
of 0.0–0.5, 0.6–1.0, 1.1–1.5, and 1.6–2.0 ng/mL, respectively. The cumulative probabilities of
developing prostate cancer at 4 years in men with baseline prostate-speciﬁc antigen of
0.0–1.0 and 1.1–2.0 ng/mL were 0.05% and 1.10%, respectively. Patients with unfavorable
clinicopathological features were diagnosed at 3 years, and at 1 year after the initial screen-
ing visit in men with baseline prostate-speciﬁc antigen levels of 0.0–1.0 and 1.1–2.0 ng/mL,
respectively.
Conclusions: The cumulative probabilities of increased prostate-speciﬁc antigen and
developing prostate cancer signiﬁcantly increase with higher baseline prostate-speciﬁc
antigen ranges. Our database could contribute to the establishment of a natural history-
adjusted screening system in the future.
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Introduction
PSA-based screening was found to benefit survival in males aged 50–69 years in the European
Randomized Study of Screening for Prostate Cancer1 and the Göteborg prospective randomized
study.2 These studies further showed that one male per 1055 screened, primarily at 4-year
intervals,1 and one male per 293 screened at 2-year intervals,2 would not suffer prostate cancer-
related death over a decade. These benefits on mortality reduction could be much greater over a
lifetime. However, it is necessary to establish an optimal screening system that maximizes the
benefits of PSA-based screening in terms of mortality reduction and cost-effectiveness, while
minimizing drawbacks of screening in terms of likelihood of overdetection.
From this point of view, setting individualized screening, including screening interval, cut-offs
for biopsy indication and upper limit of age for screening, might save on the costs of screening,
and reduce the likelihood of overdetection and false positive PSA test results, while maintaining
the benefit of mortality reduction. The Kanazawa population-based screening cohort is a database
linking individual screening results and medical information of screening-detected cancer
patients. Our database might contribute to answering the aforementioned clinical questions
regarding how to establish individualized screening systems in the future.
In the present study, the natural history of participants in the baseline PSA range of 0.0–
2.0 ng/mL during follow up for up to 12 years was investigated in terms of risk of increased PSA
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above the cut-offs of 2.0, 3.0 and 4.0 ng/mL, developing clini-
cally detectable cancer and also the likelihood of detecting
clinically insignificant cancer in the Kanazawa screening
cohort, including over 10 000 men screened annually and aged
at baseline between 55 and 68 years.
Methods
Since 2000, PSA-based screening has been provided for men
aged between 55 and 69 years in Kanazawa city, Japan.3,4 All
participants had serum total PSA levels measured using a
Tosoh II PA kit (Tosoh, Tokyo, Japan) as a primary screening
modality. Participants with serum PSA of 2.0 ng/mL or lower
did not proceed to secondary screening and were recommend to
be screened annually. In participants with PSA between 2.1 and
10.0 ng/mL, serum free PSA levels were checked using an
Immulyze Free PSA kit (Nippon DPC, Chiba, Japan).
From 2000 to 2002, participants with serum PSA levels
above 2.0 ng/mL were recommended to proceed to secondary
screening by urologists. After 2003, participants with serum
PSA above 10.0 ng/mL and those with serum free/total PSA
ratio of 0.22 or lower in the PSA range of 2.1–10.0 ng/mL were
recommended to proceed to secondary screening.3,4
PSA levels were measured again in men who proceeded to
secondary screening, and DRE and TRUS were carried out by
urologists at the urological departments. Systematic TRUS-
guided prostate biopsy was recommended in men with any
abnormal findings on rechecked PSA, DRE or TRUS. If indi-
viduals did not agree to undergo prostate biopsy or were not
recommended to undergo biopsy at the secondary screening,
they were followed up by an annual PSA test at a subsequent
population-based screening.
In patients diagnosed with prostate cancer, pathological
tumor grading was reported by local pathologists and clinical
staging was determined according to the Union for Interna-
tional Cancer Control tumor–node–metastasis classification
published in 1997,5 based on the results of DRE, TRUS com-
puted tomography, magnetic resonance imaging and bone scan
at each urological department. The aforementioned medical
information, including PSA levels at screening, biopsy results
and clinicopathological findings, were reported to the office of
the Kanazawa Medical Association.
In the Kanazawa population-based cohort, 19 640 men par-
ticipated in the screening program during the 12 years from
2000 to 2011, and 16 393 (83.5%) had serum PSA levels of
2.0 ng/mL or lower at the initial screening. Of 16 393 men,
10 653 (65.0%) participants who were aged at baseline between
55 and 68 years old and were actually screened annually at least
twice during the observation periods were enrolled into the
present study. We investigated cumulative risk of increased
PSA above 2.0, 3.0, and 4.0 ng/mL and developing prostate
cancer. We also investigated clinicopathological features of
screening-detected cancer stratified into favorable or unfavor-
able cancer according to the definition of active surveillance
studies.6,7 We handled prostate cancer with a clinical stage of
T1cN0M0, PSA below 10 ng/mL, Gleason score of 6 or less
and one or two positive cores within 6–12 systemic biopsy
cores taken as favorable cancer.
In the present retrospective study, the principles of the Dec-
laration of Helsinki were followed. Probabilities of developing
prostate cancer and PSA increase above the cut-offs were
analyzed by Kaplan–Meier analysis. The significance of differ-
ences was analyzed by the log–rank test. In analyses of
Table 1 Clinical characteristics of participants with PSA levels ≤2.0 ng/mL at the initial screening
Variables All Age range (years)
55–59 60–64 65–68
No. men 10 653 3195 4736 2722
Initial PSA (ng/mL)
Mean 0.89 0.84 0.90 0.93
Median 0.8 0.8 0.8 0.8
Initial PSA range (ng/mL)
0.0–0.5 2 804 (26.3) 911 (28.5) 1246 (26.3) 647 (23.8)
0.6–1.0 4 432 (41.6) 1397 (43.7) 1935 (40.9) 1100 (40.4)
1.1–1.5 2 246 (21.1) 612 (19.2) 1021 (21.6) 613 (22.5)
1.6–2.0 1 171 (11.0) 275 (8.6) 534 (11.3) 362 (13.3)
No. screenings
Mean 4.26 5.06 4.55 2.79
Median 4 4 4 3
Range 2–12 2–12 2–10 2–5
Initial to last screenings
Mean (day) 1 531.5 2073.0 1624.3 734.3
Median (day) 1 412 2131 1686 724
Range (day) 189–4164 189–4164 212–3418 195–1627
PSA increase
Above 2.0 ng/mL 1 405 (13.2) 453 (14.2) 710 (15.0) 242 (8.9)
Above 3.0 ng/mL 468 (4.4) 169 (5.3) 251 (5.3) 48 (1.8)
Above 4.0 ng/mL 215 (2.0) 82 (2.6) 110 (2.3) 23 (0.8)
No. prostate biopsy 309 (2.9) 112 (3.5) 160 (3.4) 37 (1.4)
No. prostate cancer 68 (0.6) 21 (0.7) 39 (0.8) 8 (0.3)
Risk of prostate cancer for men with low PSA
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probabilities, men without evidence of cancer and also PSA
increase above 2.0 ng/mL were censored at the time of last
screening. All statistical analyses were carried out using SPSS
Statistics (IBM, Armonk, NY, USA) and Prism (GraphPad
Software, San Diego, CA, USA). In all analyses, P < 0.05 was
taken to show statistical significance.
Results
The clinical characteristics of 10 653 eligible men included in
the present study are shown in Table 1. Of the 10 653 men with
baseline PSA levels of 0.0–2.0 ng/mL at the initial screen, 1405
men (13.2%) showed elevated serum PSA above 2.0 ng/mL,
and 68 (0.6%) were diagnosed with prostate cancer during the
observation period. The median duration from initial to last
screening was 3.9 years, and the median screening number was
four times.
The numbers and percentages of men with increased PSA
above 2.0, 3.0 and 4.0 ng/mL, men undergoing biopsy, and
patients diagnosed with prostate cancer, stratified by baseline
PSA ranges, are shown in Table 2. No prostate cancer patients
were detected among men with a baseline PSA of 0.0–
0.5 ng/mL during the observation period. Cumulative probabil-
ities of increased PSA above 2.0, 3.0 and 4.0 ng/mL stratified
by baseline PSA range were estimated by Kaplan–Meyer analy-
sis (Fig. 1). The probabilities of increased PSA above
2.0 ng/mL during 10 years were 7.7%, 18.3%, 57.3%, and
88.7% in men with baseline serum PSA levels of 0.0–0.5,
0.6–1.0, 1.1–1.5, and 1.6–2.0 ng/mL, respectively (Fig. 1a).
The probabilities of increased PSA above 3.0 ng/mL during 10
years were 4.1%, 6.7%, 24.6%, and 43.2% in men with baseline
serum PSA levels of 0.0–0.5, 0.6–1.0, 1.1–1.5, and 1.6–2.0 ng/
mL, respectively (Fig. 1b). The probabilities of increased serum
PSA above 4.0 ng/mL during 10 years were 2.2%, 3.6%, 9.8%,
and 23.6% in men with baseline serum PSA levels of 0.0–0.5,
0.6–1.0, 1.1–1.5, and 1.6–2.0 ng/mL, respectively (Fig. 1c).
There were significant differences in the probabilities of
increased PSA above 2.0, 3.0 and 4.0 ng/mL when comparing
men with any two different baseline PSA ranges.
The cumulative probabilities of cancer detection stratified by
PSA and age ranges at baseline are shown in Figure 2a–c. The
cumulative probability of cancer detection in men with baseline
PSA levels between 0.0 and 0.5 ng/mL was 0.0% in all age
ranges. The cumulative probabilities of developing prostate
cancer increased significantly with higher baseline PSA ranges
in all participants (Fig. 2a). We examined the likelihood of
developing cancer stratified by age range at baseline, and found
that the cumulative probability of cancer detection in men with
baseline PSA levels of 1.1–2.0 ng/mL was significantly higher
than that in men with baseline PSA levels of 0.6–1.0 ng/mL in
both the age ranges of 55–59 years and 60–64 years. However,
the difference in cumulative probability of cancer detection
between men with baseline PSA levels of 1.1–1.5 ng/mL and
1.6–2.0 ng/mL was not significant in both the age ranges of
55–59 years (Fig. 2b) and 60–64 years (Fig. 2c).
Table 3 shows the longitudinal changes in cumulative prob-
ability of cancer detection stratified by age and PSA level at
baseline. In men with baseline PSA levels of 0.0–1.0 ng/mL,
the first prostate cancer cases were detected at 5 years, 4 years
and 3 years after the initial screening visit in the age at baseline
of 55–59 years, 60–64 years and 65–68 years, respectively. In
men with baseline PSA levels of 1.1–2.0 ng/mL, the first pros-
tate cancer cases were detected at 2 years and 1 year after the
Table 2 Probability of increased PSA above cut-off and prostate cancer detection according to baseline PSA level during the observation period
Variables Baseline PSA range (ng/mL)
0.0–0.5 0.6–1.0 1.1–1.5 1.6–2.0
No. participants 2804 4432 2246 1171
No. men with increased PSA
Above 2.0 ng/mL 59 (2.1%) 261 (5.9%) 490 (21.8%) 595 (50.8%)
Above 3.0 ng/mL 28 (1.0%) 102 (2.3%) 165 (7.3%) 173 (14.8%)
Above 4.0 ng/mL 13 (0.5%) 48 (1.1) 71 (3.2) 83 (7.1)
No. men undergoing prostate biopsy 9 (0.3%) 37 (0.8%) 118 (5.3%) 145 (12.4%)
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517 461 229 129 57 No. PSA above 2.0 during period
10653 7511 4511 2371 938 234 Men remaining at the end of the period
(Years)
1.6 − 2.0 ng/mL
1.1 − 1.5 ng/mL
0.6 − 1.0 ng/mL
0.0 − 0.5 vs 0.6 − 1.0: P<0.0001
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(Years)
1.6 − 2.0 ng/mL
1.1 − 1.5 ng/mL
0.6 − 1.0 ng/mL
0.0 − 0.5 vs 0.6 − 1.0: P=0.0073
0.6 − 1.0 vs 1.1 − 1.5: P<0.0001
1.1 − 1.5 vs 1.6 − 2.0: P<0.00010.0 − 0.5 ng/mL
Fig. 1 Cumulative probabilities of ﬁrst increased PSA above (a) 2.0 ng/mL, (b)
3.0 ng/mL and (c) 4.0 ng/mL during follow up in men with baseline PSA of
2.0 ng/mL or less.
K SAWADA ET AL.
562 © 2013 The Japanese Urological Association
initial screening visit in the age at baseline of 55–64 years and
65–68 years, respectively.
The clinical characteristics of prostate cancer patients
detected in the present study are shown in Table 4. Among 68
patients, one (1.5%) had locally advanced cancer and one
(1.5%) had metastatic disease. A total of 17 (25.0%) patients
had favorable clinicopathological features that made them suit-
able for active surveillance. Table 5 shows the correlation of
baseline PSA levels and the number of years elapsed after
initial screening visit with clinicopathological characteristics of
prostate cancer stratified by suitability for active surveillance.
Among six patients diagnosed with prostate cancer at subse-
quent screening in the baseline PSA range of 0.0 to 1.0 ng/mL,
four patients were able to obtain clinicopathological features to
be stratified by suitability of active surveillance. Of these four
patients, one (25.0%) patient in whom prostate cancer was
detected at 5 years after the initial screening visit had favorable
clinicopathological features that were suitable for active sur-
veillance. In the baseline PSA range of 1.1–2.0 ng/mL, nine
patients were diagnosed with prostate cancer within 2 years
after initial screening. Of these nine patients, four (44.4%) had
prostate cancer with favorable clinicopathological features.
Discussion
It is very important to determine the natural history of prostate
cancer and to explore risk factors for the development of clini-
cally significant cancer, to establish an optimal early detection
program and treatment strategy. PSA-based screening was
found to benefit survival in previous reliable randomized
studies, but it is necessary to establish an optimal screening
system that maximizes mortality reduction and cost-
effectiveness while minimizing the drawbacks of screening,
such as overdetection, subsequent overtreatment and adverse
effects on quality of life.
The Kanazawa population-based screening cohort is pro-
spectively establishing a database including individual medical
information on screening results, subsequent biopsy results and
clinicopathological features of screening-detected cancer. In
the present study using this screening cohort, we tried to inves-
tigate the natural history of PSA in men with low PSA levels at
initial screening.
Several studies showed cumulative probabilities of increased
PSA above the cut-offs and development of prostate cancer in
subsequent screening in men with baseline serum PSA below
the cut-offs.8–12 However, the participants enrolled into these
previous studies did not undergo annual screening. In contrast,
the participants in the present study were screened annually
during the observation period, and the number of participants
was larger than in previous series.9–11 The present study showed
a natural history of participants in the baseline PSA range of
0.0–2.0 ng/mL over observation periods up to 12 years. The
longitudinal risk of increased PSA above 3.0 and 4.0 ng/mL
might have been underestimated in the present study, because
men with PSA above 2.0 ng/mL were recommended to undergo
secondary screening and subsequent prostate biopsy, and some
of these men were eliminated from the longitudinal screening
database if they were diagnosed with prostate cancer. The lon-
gitudinal risk of increased PSA above 2.0 ng/mL could be the
first reliable reference data in the field of screening for prostate
cancer.
With regard to the setting of PSA cut-offs, some previous
studies showed the importance of serum PSA level of
2.0 ng/mL as the cut-off for biopsy indication from the view-
point of cancer detection. Krumholtz et al. showed that the
detection rate of clinically important prostate cancer among
men with a serum PSA level of 2.6–4.0 ng/mL was the same as
that among men with serum PSA values greater than 4.0 ng/
mL.13 Thompson et al. showed that the rate of prostate cancer
detection was similar among men with serum PSA levels of
2.1–3.0 ng/mL and those with levels of 3.1–4.0 ng/mL.14 The
present study provided important data on the risk of developing
cancer, and also the likelihood of detecting clinically insignifi-
cant cancer in the screening cohort with the PSA cut-off for
biopsy set to 2.1 ng/mL.
In the present study, the cumulative probability of cancer
detection in men with baseline PSA of 1.1–2.0 ng/mL was
significantly higher than in those with baseline PSA of 0.0–
1.0 ng/mL. The cumulative probabilities of developing cancer
at 4 years in the men with baseline PSA of 1.1–2.0 ng/mL were
0.588%, 1.120%, and 2.719% in those with age at baseline of
55–59 years, 60–64 years, and 65–68 years, respectively. The
cumulative risk of developing cancer might be underestimated,
because this screening cohort recommended a PSA cut-off for
biopsy of 2.1 ng/mL, but this was not severely restricted by the
protocol and not all men with PSA above 2.0 ng/mL underwent
prostate biopsy. Although it would be difficult to carry out a
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4736 3893 2801 1223 211 0 Men remaining at the end of the period
(Years)
1.1 − 1.5 ng/mL
1.6 − 2.0 ng/mL
0.6 − 1.0 ng/mL
0.6 − 1.0 vs 1.1 − 1.5: P<0.0001
0.6 − 1.0 vs 1.6 − 2.0: P<0.0001
1.1 − 1.5 vs 1.6 − 2.0: P=0.0612
Fig. 2 Cumulative probabilities of developing prostate cancer during follow up
in (a) all participants, (b) men aged 55–59 years and (c) 60–64 years with baseline
PSA of 2.0 ng/mL or lower.
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developing cancer among different study cohorts because there
could be differences in the underlying background in the setting
of PSA cut-off, biopsy compliance and biopsy methods, the
age-stratified probabilities shown in the present study were
similar to those in each corresponding age group in a previous
Canadian study (0.64% in men aged 55 years and PSA of
1.5 ng/mL at baseline to 2.43% in men aged 70 years and PSA
of 2.0 ng/mL at baseline).11 Furthermore, a previous head-to-
head comparative study showed that the cumulative probability
of cancer detection in Japanese men aged 55–74 years with
baseline serum PSA of 1.0–1.9 ng/mL at 4 years was 1.3%
(95% CI 0.4–2.3%), and the results were not significantly dif-
ferent from those in Dutch men.10 They also showed that Japa-
nese and Dutch men had the same risks of increased PSA of
4.0 ng/mL or greater after controlling for age and baseline PSA
level.10 The cumulative probability of freedom from PSA
increases to levels >4.0 ng/mL after 4 years of observation were
also almost the same in the USA black and USA white popu-
lations, if baseline PSA levels fell within the same range.15
Therefore, there might be no ethnic differences in the likelihood
of developing prostate cancer in men with the same baseline
PSA level and age. These studies support the hypothesis that
baseline PSA could be a key issue for establishing an interna-
tionally standardized and optimal screening system regardless
of race.
In contrast, there is a growing awareness of the potential for
overdiagnosis and overtreatment for “insignificant” cancer
detected at PSA-based screening, especially using low serum
PSA cut-off levels. Therefore, it is also important to clarify
clinicopathological features of prostate cancer detected within
the screening system. In the present study, there were few
patients in advanced stages of prostate cancer, including clini-
cal stage T3 or higher (2.9%), and serum PSA at diagnosis of
10.0 ng/mL or greater (2.9%). In contrast, 63.2% of the patients
had unfavorable clinicopathological features that referred
excluding criteria for active surveillance studies.6,7 A previous
study using an accelerated failure time model suggested that
men with serum PSA between 1.0 and 1.5 ng/mL should be
screened every second year, and men with PSA 1.5 ng/mL or
greater should be screened every year.11 The Japanese
Urological Association guidelines for PSA-based screening
proposed a baseline PSA-adjusted screening interval, which
was set every 3 years and annually in men with baseline PSA
of 0.0–1.0 ng/mL and 1.1–2.0 ng/mL, respectively.16 In the
present study, all cancer cases with unfavorable clinico-
pathological features were diagnosed at least 3 years after the
initial screening visit in men with baseline PSA levels of 0.0–
1.0 ng/mL. In contrast, there was a risk of developing cancer
with unfavorable features within 1 year after the initial
screening visit in men with baseline PSA of 1.1–2.0 ng/mL.
Furthermore, prostate cancer cases with unfavorable clinico-
pathological features were detected every year, including one
case with metastatic lesions diagnosed at 5 years after the initial
Table 3 Longitudinal changes in the cumulative probability of prostate cancer detection stratiﬁed by age and PSA level at baseline
PSA and age
at baseline
No. men Cumulative percentages of prostate cancer detection (95% CI) at speciﬁed elapsed years after initial screening
1 Year 2 Years 3 Years 4 Years 5 Years 8 Years
0.0–1.0 ng/mL
All 7236 0 0 0.020 (0–0.06) 0.045 (0–0.11) 0.145 (0.02–0.27) 0.186 (0.03–0.34)
55–59 years 2308 0 0 0 0 0.143 (0–0.20) 0.224 (0–0.48)
60–64 years 3181 0 0 0 0.045 (0–0.14) 0.108 (0–0.26) 0.108 (0–0.26)
65–68 years 1747 0 0 0.146 (0–0.43) 0.146 (0–0.43) NA NA
1.1–2.0 ng/mL
All 3417 0.031 (0–0.09) 0.313 (0.11–0.52) 0.580 (0.29–0.88) 1.098 (0.65–1.55) 1.826 (1.19–2.46) 5.633 (3.97–7.30)
55–59 years 887 0 0.126 (0–0.37) 0.268 (0–0.37) 0.588 (0.01–1.17) 0.765 (0.09–1.44) 3.835 (1.91–5.74)
60–64 years 1555 0 0.292 (0.01–0.57) 0.624 (0.19–1.06) 1.120 (0.51–1.73) 2.246 (1.30–3.20) 6.598 (3.86–9.34)
65–68 years 975 0.113 (0–0.33) 0.553 (0.01–1.10) 0.829 (0.06–1.60) 2.719 (0.02–5.42) NA NA
Table 4 Clinical characteristics of patients diagnosed with prostate cancer
within subsequent screening in men with baseline PSA between 0.0 and
2.0 ng/mL
Characteristics No. patients (%)














T1c N0 M0 45 (66.2)
T2 N0 M0 18 (26.5)
T3a N0 M0 1 (1.5)
T3a N0 M1b 1 (1.5)
Unknown 3 (4.4)




Suitability for active surveillance
Yes (PSA <10.0, T1c, GS ≤6 and positive
biopsy cores ≤2)
17 (25.0)
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screening visit in this baseline PSA range.Although the number
of cancer cases detected was small, our results support the
recommendation for screening interval proposed by the Japa-
nese guidelines.16
The primary goal of PSA-based population screening is to
detect prostate cancer before cancer cells spread to the adjacent
organs, lymph nodes or distant organs to save lives and to
maintain quality of life by appropriate treatment strategies.
Therefore, setting natural history-adjusted rescreening intervals
should be carefully considered. We could provide a clue for
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Table 5 Correlation of baseline PSA levels and number of elapsed years after initial screening with clinicopathological characteristics of prostate cancer stratiﬁed by
suitability for active surveillance
Baseline PSA and cancer characteristics No. patients detected at each year after initial screening visit
1 Years 2 Years 3 Years 4 Years 5 Years 8 Years 10 Years
Baseline PSA of 0.0–1.0 ng/mL
Patient suitable for AS criteria (PSA <10.0, T1c, GS ≤6 and positive cores ≤2) 1
Patients unﬁt for AS criteria (PSA ≥10.0 or ≥ T2 or GS ≥7 or positive cores ≥3) 1 1 1
Baseline PSA of 1.1–2.0 ng/mL
Patient suitable for AS criteria (PSA <10.0, T1c, GS ≤6 and positive cores ≤2) 4 1 3 2 6
Patients unﬁt for AS criteria (PSA ≥10.0 or ≥ T2 or GS ≥7 or positive cores ≥3) 1 4 5 4 7 17 2
Patients with metastatic disease (1)
Risk of prostate cancer for men with low PSA
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